DK0882130T3 - Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette - Google Patents

Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette

Info

Publication number
DK0882130T3
DK0882130T3 DK97907609T DK97907609T DK0882130T3 DK 0882130 T3 DK0882130 T3 DK 0882130T3 DK 97907609 T DK97907609 T DK 97907609T DK 97907609 T DK97907609 T DK 97907609T DK 0882130 T3 DK0882130 T3 DK 0882130T3
Authority
DK
Denmark
Prior art keywords
recognized
antigen
cancer
peptide
derived
Prior art date
Application number
DK97907609T
Other languages
English (en)
Other versions
DK0882130T5 (da
Inventor
Rong-Fu Wang
Steven A Rosenberg
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of DK0882130T3 publication Critical patent/DK0882130T3/da
Application granted granted Critical
Publication of DK0882130T5 publication Critical patent/DK0882130T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00—Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20—Immunohistochemistry assay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer
DK97907609T 1996-02-09 1997-02-06 Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette DK0882130T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/599,602 US5840839A (en) 1996-02-09 1996-02-09 Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US08/725,736 US5831016A (en) 1996-02-09 1996-10-04 Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
PCT/US1997/002186 WO1997029195A2 (en) 1996-02-09 1997-02-06 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same

Publications (2)

Publication Number Publication Date
DK0882130T3 true DK0882130T3 (da) 2004-03-08
DK0882130T5 DK0882130T5 (da) 2004-05-17

Family

ID=24400301

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03022671T DK1411124T3 (da) 1996-02-09 1997-02-06 Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette
DK97907609T DK0882130T5 (da) 1996-02-09 1997-02-06 Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03022671T DK1411124T3 (da) 1996-02-09 1997-02-06 Humant cancerantigen fra tyrosinase-beslægtet protein 1 og gener, der koder dette

Country Status (12)

Country Link
US (4) US5840839A (da)
EP (3) EP0882130B1 (da)
JP (1) JP3998713B2 (da)
AT (2) ATE391780T1 (da)
AU (1) AU729497B2 (da)
CA (2) CA2245702C (da)
CY (1) CY2422B1 (da)
DE (2) DE69725428T2 (da)
DK (2) DK1411124T3 (da)
ES (2) ES2305379T3 (da)
PT (2) PT882130E (da)
WO (1) WO1997029195A2 (da)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
EP0974663A1 (en) * 1993-06-25 2000-01-26 Smithkline Beecham Plc Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US7282198B2 (en) * 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7335351B2 (en) * 1997-03-19 2008-02-26 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
PT1003850E (pt) * 1997-06-06 2009-08-13 Dynavax Tech Corp Inibidores da actividade de sequências de adn imunoestimulantes
US6043084A (en) * 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
WO1999018206A2 (en) * 1997-10-08 1999-04-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human cancer antigen ny eso-1/cag-3 and gene encoding same
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
AU743066B2 (en) * 1997-11-06 2002-01-17 Roche Diagnostics Gmbh Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
JP3559894B2 (ja) 1998-04-01 2004-09-02 日産自動車株式会社 樹脂製ウィンドウ及びその製法
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US7052830B1 (en) 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
EP2036573A1 (en) * 1998-06-17 2009-03-18 IDM Pharma, Inc. HLA binding peptides and their uses
KR100653590B1 (ko) * 1998-06-25 2006-12-04 교고 이또 시클로필린 ｂ 유래의 종양 항원 펩티드
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
ATE420112T1 (de) * 1998-07-31 2009-01-15 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
WO2000013699A1 (en) * 1998-09-04 2000-03-16 Ludwig Institute For Cancer Research An antigenic peptide encoded by an alternative open reading frame of human macrophage colony-stimulating factor
AU1598500A (en) * 1998-10-26 2000-05-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
DK1165778T3 (da) * 1999-03-11 2007-02-12 Glaxosmithkline Biolog Sa Anvendelser af CASB618-polynukleotider og -polypeptider
US6389376B1 (en) * 1999-07-26 2002-05-14 Sun Microsystems, Inc. Method and apparatus for generating n-segment steiner trees
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
JP4540033B2 (ja) 1999-10-22 2010-09-08 サノフィ パストゥール リミテッド 腫瘍抗原に対する免疫応答を誘発および／または増強する方法
US6573050B1 (en) 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US7795379B2 (en) * 1999-11-30 2010-09-14 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US6774226B1 (en) * 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
EP2333065B1 (en) 2000-01-28 2017-03-15 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services MHC class II restricted T cell epitopes from the cancer antigen NY ESO-1
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
US20040138135A1 (en) * 2000-05-31 2004-07-15 Nicolette Charles A. Therapeutic compounds for ovarian cancer
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
AU2002227498A1 (en) * 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
JP4503801B2 (ja) * 2000-09-08 2010-07-14 独立行政法人科学技術振興機構 新規ヒト癌・精巣抗原及びその遺伝子
ATE520772T1 (de) * 2000-10-31 2011-09-15 Eisai Inc Nucleinsäure kodierend für cyp1b1 und methoden zur verwendung
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
DE10061299A1 (de) * 2000-12-08 2002-06-27 Siemens Ag Vorrichtung zur Feststellung und/oder Weiterleitung zumindest eines Umwelteinflusses, Herstellungsverfahren und Verwendung dazu
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
CA2439492A1 (en) * 2001-02-26 2002-09-06 Imclone Systems Incorporated Tri-hybrid melanoma antigen
US7252824B2 (en) * 2001-03-07 2007-08-07 Mannkind Corporation Anti-neovasculature preparations for cancer
CA2441809C (en) 2001-03-27 2014-07-22 Biomira, Inc. Liposomal vaccines comprising dilipopeptides for modulating t1 and t2 immune responses
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
AU2002327614B2 (en) * 2001-09-06 2007-12-06 Alphavax, Inc. Alphavirus replicon vector systems
US7202045B2 (en) 2001-09-19 2007-04-10 Regents Of The University Of Michigan Detection and treatment of cancers of the lung
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
US20030119079A1 (en) * 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
US7449548B2 (en) 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
US20030148285A1 (en) * 2001-12-20 2003-08-07 Claude Perreault Mammalian SIMP protein, gene sequence and uses thereof in cancer therapy
JP4376629B2 (ja) * 2002-01-08 2009-12-02 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
DE10221411B4 (de) * 2002-05-14 2004-07-08 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Rekombinantes Fowlpox-Virus
FR2840530B1 (fr) * 2002-06-11 2004-12-24 Oreal Composition cosmetique comprenant un agent inducteur de l'expression de la dopachrome tautomerase (trp-2) pour lutter contre la canitie
WO2004016733A2 (en) * 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2510238A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
EP1585812B1 (en) * 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
ES2630222T3 (es) * 2002-12-13 2017-08-18 Alphavax, Inc. Partículas alfavíricas y métodos de preparación
ES2543084T3 (es) * 2003-02-18 2015-08-14 Baylor College Of Medicine Activación inducida en células dendríticas
CA2514288C (en) * 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
PT1651666E (pt) * 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
DE602004031116D1 (de) * 2003-07-22 2011-03-03 Ludwig Inst For Cancer Res New York Von hla-klasse-ii-molekülen präsentierte ssx-2-peptide
US20050202036A1 (en) * 2003-07-22 2005-09-15 Branch Andrea D. Alternate reading frame polypeptides drived from hepatitis C and methods of their use
US20080081045A1 (en) * 2003-10-14 2008-04-03 Biomira, Inc. Combination Therapy for Cancer
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
ATE462003T1 (de) * 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
TW201204410A (en) * 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
ATE420965T1 (de) * 2004-05-18 2009-01-15 Alphavax Inc Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20070009484A1 (en) * 2005-02-08 2007-01-11 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
SG162818A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Multivalent entrain-and-amplify immunotherapeutics for carcinoma
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
CN105194650A (zh) * 2005-06-28 2015-12-30 肿瘤防护公司 用一种粘蛋白状糖蛋白(muc-1)疫苗治疗患者的方法
EP1910839B1 (en) * 2005-07-27 2016-04-27 Oncotherapy Science, Inc. Colon cancer related gene tom34
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
ATE545708T1 (de) * 2005-11-14 2012-03-15 Univ Laval Krebsantigen mage-a9 und verwendungen davon
PL1951283T3 (pl) * 2005-11-16 2010-12-31 Pantarhei Bioscience Bv Kompozycje farmaceutyczne do leczenia i zapobiegania rakowi jajnika
EP1994181A4 (en) * 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
US9732131B2 (en) * 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US8129184B2 (en) * 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US8097256B2 (en) * 2006-09-28 2012-01-17 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
WO2008049113A2 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
NZ582495A (en) * 2007-06-21 2012-05-25 Alphavax Inc Promoterless cassettes for expression of alphavirus structural proteins
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
MX2010010021A (es) 2008-03-12 2011-02-15 Imclone Llc Anticuepos anti-tyrp1.
WO2009149094A2 (en) * 2008-06-02 2009-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cytotoxic t cell defined egfr peptide and an optimized derivative peptide
JP5715051B2 (ja) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リポソーム、抗原、ポリヌクレオチド及び疎水性物質の連続相を含む担体を含む組成物
DK2328923T3 (da) 2008-09-02 2016-03-21 Cedars Sinai Medical Center Cd133-epitoper
AU2009292996B2 (en) 2008-09-22 2015-04-23 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing CD40 and pattern recognition receptor adapters
WO2010121180A1 (en) 2009-04-17 2010-10-21 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US9125849B2 (en) 2010-12-02 2015-09-08 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same
CN103781469B (zh) 2011-02-24 2015-09-16 肿瘤防护公司 含有佐剂的以muc1为基础的糖脂肽疫苗
IN2014CN02581A (da) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9653272B2 (en) 2012-06-26 2017-05-16 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
WO2014091034A1 (en) * 2012-12-14 2014-06-19 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Novel mhc-independent tumor-associated antigens
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
WO2014151960A2 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
EP3607974A1 (en) * 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
AU2014242916B2 (en) 2013-03-28 2018-08-02 Invectys A cancer vaccine for dogs
CA2908138A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for cats
DK3004329T3 (da) 2013-06-05 2020-05-18 Bellicum Pharmaceuticals Inc Fremgangsmåder til induktion af delvis apoptose under anvendelse af caspasepolypeptider
EA035485B1 (ru) 2013-10-28 2020-06-24 Инвектис Электроперенос генов в клетки кожи
BR112016009002B1 (pt) 2013-10-28 2023-05-02 Invectys Construção de ácido nucleico e usos de uma construção de ácido nucleico
TR201908418T4 (tr) 2013-11-04 2019-07-22 Uti Lp Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
WO2015123527A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
JP6868554B2 (ja) 2014-09-02 2021-05-12 ベリカム ファーマシューティカルズ， インコーポレイテッド ＭｙＤ８８およびＣＤ４０ポリペプチドによるキメラ抗原受容体の共刺激
PL3193917T3 (pl) * 2014-09-17 2022-01-17 Io Biotech Aps Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty
US10189880B2 (en) 2014-11-03 2019-01-29 Leiden University Medical Center T cell receptors directed against Bob1 and uses thereof
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
ES2805085T3 (es) * 2015-01-16 2021-02-10 Glyp Holdings Pty Ltd Epítopos de glipicano y usos de éstos
JP6028253B2 (ja) * 2015-01-28 2016-11-16 学校法人北里研究所 癌細胞の検出方法及び癌細胞検出キット
US20160263155A1 (en) 2015-03-10 2016-09-15 Leiden University Medical Center T cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物
US10166255B2 (en) 2015-07-31 2019-01-01 Regents Of The University Of Minnesota Intracellular genomic transplant and methods of therapy
WO2017177207A1 (en) * 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
GB2605540B (en) 2016-10-18 2022-12-21 Univ Minnesota Tumor infiltrating lymphocytes and methods of therapy
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
US20210147507A1 (en) 2017-05-09 2021-05-20 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
CN110996971A (zh) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 创建个性化犬癌症疫苗的方法
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
CN109293739B (zh) * 2018-01-24 2021-03-30 中国疾病预防控制中心病毒病预防控制所 一种a3超家族通用肿瘤抗原多肽及其应用
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP3793576A4 (en) 2018-05-15 2022-04-06 Globeimmune, Inc. RECOMBINANT YEAST LYSATES FOR INDUCING CELLULAR IMMUNE RESPONSE
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
AU4683093A (en) * 1992-07-20 1994-02-14 Merck & Co., Inc. Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
NZ255683A (en) * 1992-08-07 1996-08-27 Cytel Corp Immunogenic composition comprising a 9-10 aa residue peptide having a hla-a3.2, hla-a1, hla-a11 or hla-a24.1 binding motif
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation

Also Published As

Publication number Publication date
WO1997029195A3 (en) 1997-11-13
ATE251670T1 (de) 2003-10-15
DK1411124T3 (da) 2008-08-04
AU1957297A (en) 1997-08-28
JP3998713B2 (ja) 2007-10-31
DE69738630D1 (de) 2008-05-21
CA2245702A1 (en) 1997-08-14
AU729497B2 (en) 2001-02-01
EP0882130B1 (en) 2003-10-08
ES2206685T3 (es) 2004-05-16
DE69738630T2 (de) 2009-05-07
EP1411124A3 (en) 2004-09-29
CA2733866C (en) 2015-01-27
DE69725428D1 (de) 2003-11-13
DE69725428T2 (de) 2004-07-29
US5831016A (en) 1998-11-03
CA2245702C (en) 2011-10-04
JP2000506380A (ja) 2000-05-30
ATE391780T1 (de) 2008-04-15
CY2422B1 (en) 2004-11-12
US5840839A (en) 1998-11-24
EP0882130A2 (en) 1998-12-09
EP1092770A3 (en) 2003-06-04
PT882130E (pt) 2004-02-27
EP1092770A2 (en) 2001-04-18
WO1997029195A2 (en) 1997-08-14
US6087110A (en) 2000-07-11
EP1411124B1 (en) 2008-04-09
EP1411124A2 (en) 2004-04-21
CA2733866A1 (en) 1997-08-14
PT1411124E (pt) 2008-07-04
US6132980A (en) 2000-10-17
ES2305379T3 (es) 2008-11-01
DK0882130T5 (da) 2004-05-17

Similar Documents

Publication Publication Date Title
DK0882130T3 (da) Humant cancerantigen i tyrosinase-beslægtet protein 1 og gen, der koder dette
DK0932678T3 (da) En familie af gener kodende for apoptoserelaterede peptider, peptider kodet deraf og fremgangsmåde til anvendelse deraf
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
ES8802249A1 (es) Un procedimiento para el aislamiento de un gen de relaxina de un ser humano u otro primate o de una especie relacionada
DE69435075D1 (de) , die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
ES8801671A1 (es) Un procedimiento para preparar relaxina humana o sus analogos
ATE356206T1 (de) Menschliches krebsantigen ny eso-1/cag-3 und dazu kodierendes gen
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002094859A3 (en) Mage-a1 peptides for treating or preventing cancer
IE20000918A1 (en) GP75 As a Tumor Vaccine for Melanoma
ATE175719T1 (de) Epididymis-spezifische polypeptide und deren verwendung
WO2002044202A3 (fr) Peptides immunogeniques mutes derives de r9m, polynucleotides les codant et leurs usages therapeutiques
EP1233024A3 (en) 25466, a human transporter family member and uses therefor
MY127669A (en) Polypeptide hormone phosphatonin
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
Niewold et al. Equine light-chain-associated amyloidosis
EP0787798A3 (en) GRP17 gene